49 results about "Agonist drugs" patented technology

Optimal ratios of pharmaceutical compositions of beta-1 and beta-2 agonists with their respective antagonists. Safer, more cost-effective drugs for heart and lung therapies are made by combining specific antagonists with their agonists to prevent desensitization of cellular receptors, reducing some of the unwanted side-effects of the agonist drugs alone. Determining the optimal concentration of an antagonist or inhibitor, which is necessary to prevent desensitization, without causing unnecessary and unwanted inhibition, creates a new class of pharmaceuticals. To derive an optimum ratio for a specific composition, a formulative method is provided to detail how competitive antagonists of the receptor should be combined with agonists, in specific proportions, to maximize and maintain receptor response throughout drug administration. The "optimal ratio" methodology used to determine a specific agonist / antagonist composition, to prevent beta-1 or beta-2 receptor desensitization, is experimentally verified and validated for specific compositions. Alteration of a specific ratio is practiced to account for the pharmacokinetic / dynamic differences between animals and humans and within human populations.

The invention discloses resolution of a D1 dopamine receptor agonist drug and in particular discloses a resolution method of fenoldopam. The resolution method of the D1 dopamine receptor agonist drug comprises the steps of protecting a phenolic hydroxyl group and an amino group in the structure of fenoldopam, then carrying out chemical resolution with a chiral acidic resolution agent to obtain a pure optical isomer, and finally removing a protecting group and salifying to obtain optically pure methanesulfonic acid fenoldopam.

A solid pharmaceutical composition for oral administration comprising tegaserod in base or salt form in an amount of up to 10% by weight a bulking agent in an amount of 70 to 90% by weight a disintegrant in an amount of less than 15% by weight a glidant and a lubricant,

Methods for screening for therapies against autism spectrum disorders and methods for determining whether a subject would be responsive to a therapy against an autism spectrum disorder are disclosed.

The present invention provides a cell strain and a detection method for detecting the activity of an antibody-immune agonist conjugated drug. ‑Immune agonist receptors and immune signaling pathway reporter genes in immune agonist drug conjugates. The cell line of the present invention can be used for the activity detection of different target antigens and immune agonist conjugated drugs with different activity levels. The detection method of the present invention can overcome the shortcomings of the co-culture method of PBMC and antigen-positive cells, and has the advantages of simple operation, low cost, higher sensitivity, larger detection dynamic range, and the like, and the antibody obtained by the detection method of the present invention has the advantages of ‑The activity results of the immune agonist-conjugated drug are closer to the results of in vivo efficacy experiments.